Jenburkt Pharmaceutical L
NSE: JENBURPH · Pharmaceuticals · sector
₹874.55NSE close 2026-10-26
Key numbers
Market cap₹386 cr
Price₹874.55
52w high / low₹1,074 / ₹864
P/E11.8xSector median 27.9x
P/B2.0xSector median 2.9x
Book value₹446.5
Dividend yield2.05%Sector median 0.48%
ROE17.8%Sector median 11.7%
ROCE22.1%Sector median 12.3%
OPM21.9%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA9.0xSector median 18.6x
Interest cover90.4x
Current ratio4.11x
Sales growth 3y+7.3%Sector median +9.6%
Profit growth 3y+12.2%Sector median +13.3%
PEG0.87x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹53 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 90.4x in the last 12 months.
- Other income was 30% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹874.55 on 2026-10-26: -18.6% from the 52-week high, +1.2% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,364.55 · low ₹874.55
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 41 | 36 | 46 | 43 | 45 | 36 |
| EBITDA | 11 | 9 | 13 | 7 | 10 | 6 |
| OPM % | 26.5% | 25.2% | 28.8% | 17.3% | 23.1% | 17.0% |
| Other income | 2 | 2 | 2 | 2 | 4 | 2 |
| Net profit | 9 | 8 | 10 | 6 | 11 | 6 |
| EPS (₹) | 19.34 | 17.66 | 23.03 | 13.44 | 24.58 | 13.34 |
| Revenue YoY | +8.7% | -0.1% | ||||
| Profit YoY | +27.0% | -24.4% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 124 | 137 | 142 | 152 | 169 | 169 |
| EBITDA | 27 | 30 | 33 | 40 | 40 | 37 |
| Net profit | 22 | 25 | 26 | 32 | 35 | 33 |
| EPS (₹) | 48.58 | 53.90 | 58.86 | 72.65 | 78.71 | 74.39 |
| Revenue growth | +10.3% | +3.8% | +6.8% | +11.2% | – | |
| Profit growth | +10.4% | +5.6% | +23.4% | +8.4% | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +7.3% | – | – |
| Net profit | +12.2% | – | – |
| EPS | +13.5% | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 172 | 197 |
| Borrowings | 2 | 0 |
| Cash & equivalents | 25 | 53 |
| Total assets | 196 | 226 |
| Fixed assets | 14 | 19 |
| Capital work in progress | 40 | 46 |
| Investments | 21 | 27 |
| Receivables | 21 | 24 |
| Inventory | 9 | 14 |
| Payables | 8 | 8 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 28 | 27 |
| Cash from investing | -17 | -19 |
| Cash from financing | -8 | -9 |
| Capex | 20 | 14 |
| Free cash flow | 8 | 13 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 18.7% | 17.6% |
| ROCE % | 25.5% | 23.8% |
| Debtor days | 50 | 53 |
| Inventory days | 109 | 154 |
| Payable days | 100 | 91 |
| Cash conversion cycle (days) | 59 | 116 |
| Working capital days | 91 | 156 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| JENBURPH | ₹386 cr | 11.8x | 2.0x | 17.8% | 22.1% | 21.9% | +7.3% | 2.05% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-08-28 | Dividend | Dividend - Rs 20.70 Per Share |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | JENBURPH |
| BSE code | 524731 |
| ISIN | INE354A01013 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = NSE close 2026-10-26.